<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01810770</url>
  </required_header>
  <id_info>
    <org_study_id>15397</org_study_id>
    <nct_id>NCT01810770</nct_id>
  </id_info>
  <brief_title>Radium-223 Dichloride Asian Population Study in the Treatment of CRPC Patients With Bone Metastasis</brief_title>
  <official_title>A Single-arm, International, Prospective, Interventional, Open-label, Multicenter Study of Radium-223 Dichloride in the Treatment of Patients With Castration-Resistant Prostate Cancer (CRPC) With Bone Metastasis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and efficacy (Overall survival [OS]) of multiple doses of Ra-223
      dichloride in an Asian population of subjects with CRPC metastatic to the bone.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 26, 2013</start_date>
  <completion_date type="Actual">September 25, 2017</completion_date>
  <primary_completion_date type="Actual">September 25, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events as a measure of safety and tolerability</measure>
    <time_frame>Up to 36 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with laboratory changes</measure>
    <time_frame>Up to 36 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with changes in vital signs</measure>
    <time_frame>Up to 36 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with changes in electrocardiogram (ECG)</measure>
    <time_frame>Up to 36 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>OS is defined as the time from date of first study drug treatment to death due to any cause. Subjects still alive at the time of analysis were censored at their last date of last contact.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in total Alkaline Phosphate (ALP) in serum</measure>
    <time_frame>Up to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with total-ALP normalization</measure>
    <time_frame>Up to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to total ALP progression</measure>
    <time_frame>Up to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in prostate specific antigen (PSA) in serum</measure>
    <time_frame>Up to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to PSA progression</measure>
    <time_frame>Up to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first skeletal related event (SRE)</measure>
    <time_frame>Up to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SRE free survival</measure>
    <time_frame>Up to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to occurrence of first use of radio-isotopes to relieve skeletal symptoms</measure>
    <time_frame>Up to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to occurrence of first start of any other anti-cancer treatment</measure>
    <time_frame>Up to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to occurrence of first deterioration of Eastern Cooperative Oncology Group (ECOG) Performance Status (PS)</measure>
    <time_frame>Up to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (QoL)</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>QoL is assessed by the scores got from the Functional Assessment of Cancer Therapy in subjects with prostate cancer (FACT-P) questionnaire, EuroQoL (EQ-5D) questionnaire, and the BPI-SF questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to pain progression</measure>
    <time_frame>Up to 36 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">243</enrollment>
  <condition>Prostatic Neoplasms</condition>
  <arm_group>
    <arm_group_label>Radium-223 dichloride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Radium-223 dichloride (Xofigo, BAY88-8223)</intervention_name>
    <description>Radium-223 dichloride, 55 kBq/kg body weight, will be administered as a slow bolus IV injection at 4 week intervals for up to 6 doses.</description>
    <arm_group_label>Radium-223 dichloride</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed adenocarcinoma of the prostate

          -  Patients diagnosed with progressive bone predominant metastatic Castration-Resistant
             Prostate Cancer (CRPC) /Hormone Refractory Prostate Cancer (HRPC) with at least 2
             skeletal metastases on imaging with no lung, liver, and/or brain metastasis (lymph
             node only metastasis is allowed)

          -  Known hormone refractory disease

          -  No intention to use cytotoxic chemotherapy within the next 6 months

          -  Either regular (not occasional) analgesic medication use for cancer related bone pain
             or treatment with external bean radiation therapy (EBRT) for bone pain within previous
             12 weeks

          -  Age &gt;/= 18 years

          -  Race is Asian

          -  Eastern Co-operative Oncology Group (ECOG) Performance Status (PS): 0-2

          -  Life expectancy &gt;/= 6 months

          -  Adequate bone marrow, liver and renal function as assessed by the Laboratory required
             by protocol

        Exclusion Criteria:

          -  Treatment with an investigational drug within previous 4 weeks prior to screening, or
             planned during the treatment or follow-up periods

          -  Eligible for docetaxel treatment, i.e. subjects who are fit enough, willing and who
             are located where treatment with docetaxel is available

          -  Treatment with cytotoxic chemotherapy within previous 4 weeks prior to screening, or
             failure to recover from adverse events due to cytotoxic chemotherapy administered more
             than 4 weeks prior to screening (however ongoing neuropathy is permitted)

          -  Prior hemibody external radiotherapy is excluded. Subjects who received other types of
             prior external radiotherapy are allowed provided that the bone marrow function is
             assessed and meets the protocol requirements for hemoglobin, absolute neutrophil count
             and platelets.

          -  Received systemic therapy radionuclides (e.g., strontium-89, samarium-153,
             rhenium-186, rhenium-188, or radium-223 dichloride) for the treatment of bony
             metastases

          -  Blood transfusion or erythropoetin stimulating agents within the previous 4 weeks
             prior to screening

          -  Other malignancy treated within the last 3 years (except non-melanoma skin cancer or
             low-grade superficial bladder cancer)

          -  Visceral metastases as assessed by abdominal/pelvic computed tomography (CT) or other
             imaging modality

          -  Presence of brain metastases

          -  Lymphadenopathy exceeding 3 cm in short-axis diameter

          -  Any size pelvic lymphadenopathy if it is thought to be a contributor to concurrent
             hydronephrosis

          -  Imminent or established spinal cord compression based on clinical findings and/or
             magnetic resonance imaging (MRI). Subjects with history of spinal cord compression
             should have completely recovered.

          -  Received local practice implant therapy containing lodine-125 or Palladium-103 for the
             primary lesion of prostate cancer within the 6 months prior to screening.

          -  Any other serious illness or medical condition
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210008</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210009</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beijing</city>
        <zip>100020</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beijing</city>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beijing</city>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beijing</city>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beijing</city>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shanghai</city>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shanghai</city>
        <zip>200072</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shanghai</city>
        <zip>200127</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shanghai</city>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Donggu,</city>
        <state>Gwangju Gwang''yeogsi</state>
        <zip>61469</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Singapore</city>
        <zip>119228</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Singapore</city>
        <zip>258499</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taipei City</city>
        <state>Taipei</state>
        <zip>112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kaohsiung</city>
        <zip>81362</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taoyuan</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
    <country>Korea, Republic of</country>
    <country>Singapore</country>
    <country>Taiwan</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 12, 2013</study_first_submitted>
  <study_first_submitted_qc>March 12, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 14, 2013</study_first_posted>
  <last_update_submitted>March 29, 2018</last_update_submitted>
  <last_update_submitted_qc>March 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Radium-223 Dichloride</keyword>
  <keyword>Prostatic Neoplasms</keyword>
  <keyword>Bone Metastasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Radium Ra 223 dichloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

